Will Insurers Pay For Sarepta’s DMD Drug?

Shares of Sarepta Therapeutics ( SRPT ) dropped almost 6% today to trade just under $30 in recent market action. What gives? It seems that an analyst at Jefferies is predicting pricing pushback from insurers for Exondys 51, the controversial therapy for Duchenne Muscular Dystrophy that received FDA approval in September.